<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876054</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10279</org_study_id>
    <nct_id>NCT03876054</nct_id>
  </id_info>
  <brief_title>Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator</brief_title>
  <acronym>REALITY</acronym>
  <official_title>Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The REALITY study is a prospective, post-market, non-randomized, multi-center, single-arm,&#xD;
      open-label study intended to collect short- and long-term safety and effectiveness data on&#xD;
      various populations implanted with Abbott's neurostimulation systems.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has broad inclusion criteria and minimal exclusion criteria to ensure the results&#xD;
      are representative of the real-world use of these devices. Enrollment caps will be&#xD;
      implemented to ensure patients from approved indications are represented. Individuals who are&#xD;
      scheduled to receive an implantable Abbott neurostimulation system are eligible for study&#xD;
      consideration. The study will enroll up to 2,000 subjects from up to 100 participating&#xD;
      centers. Subject enrollment is expected to be completed within 7 years; subjects will be&#xD;
      followed for 5 years. The total duration of the study is expected to be 13 years, including&#xD;
      enrollment, data collection from all subjects, and study close out.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">June 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>Baseline</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>Permanent Implant Procedure</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>6 months</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>9 months</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>1 Year</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>1.5 Years</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>2 Years</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>2.5 Years</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>3 Years</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>3.5 Years</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>4 Years</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>4.5 Years</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of device and procedure related adverse events, deaths, and device deficiencies</measure>
    <time_frame>5 Years</time_frame>
    <description>Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by PROMIS-29</measure>
    <time_frame>6 months</time_frame>
    <description>The PROMIS-29 is used to estimate overall quality of life by assessing the following domains known to impact activities of daily living: physical function, sleep disturbance, depression, anxiety, fatigue, pain interference, pain intensity, and social role satisfaction. The scale requires subjects to rate the frequency and/or severity of symptoms and experiences related to each of these domains. The final item is an 11-point pain intensity numerical rating scale (NRS) by which the subject rates their average pain over the past 7 days. Subjects should read each item and check the one box that most closely represents their response.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by PROMIS-29</measure>
    <time_frame>1 Year</time_frame>
    <description>The PROMIS-29 is used to estimate overall quality of life by assessing the following domains known to impact activities of daily living: physical function, sleep disturbance, depression, anxiety, fatigue, pain interference, pain intensity, and social role satisfaction. The scale requires subjects to rate the frequency and/or severity of symptoms and experiences related to each of these domains. The final item is an 11-point pain intensity numerical rating scale (NRS) by which the subject rates their average pain over the past 7 days. Subjects should read each item and check the one box that most closely represents their response.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by PROMIS-29</measure>
    <time_frame>2 Years</time_frame>
    <description>The PROMIS-29 is used to estimate overall quality of life by assessing the following domains known to impact activities of daily living: physical function, sleep disturbance, depression, anxiety, fatigue, pain interference, pain intensity, and social role satisfaction. The scale requires subjects to rate the frequency and/or severity of symptoms and experiences related to each of these domains. The final item is an 11-point pain intensity numerical rating scale (NRS) by which the subject rates their average pain over the past 7 days. Subjects should read each item and check the one box that most closely represents their response.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by PROMIS-29</measure>
    <time_frame>3 Years</time_frame>
    <description>The PROMIS-29 is used to estimate overall quality of life by assessing the following domains known to impact activities of daily living: physical function, sleep disturbance, depression, anxiety, fatigue, pain interference, pain intensity, and social role satisfaction. The scale requires subjects to rate the frequency and/or severity of symptoms and experiences related to each of these domains. The final item is an 11-point pain intensity numerical rating scale (NRS) by which the subject rates their average pain over the past 7 days. Subjects should read each item and check the one box that most closely represents their response.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by PROMIS-29</measure>
    <time_frame>4 Years</time_frame>
    <description>The PROMIS-29 is used to estimate overall quality of life by assessing the following domains known to impact activities of daily living: physical function, sleep disturbance, depression, anxiety, fatigue, pain interference, pain intensity, and social role satisfaction. The scale requires subjects to rate the frequency and/or severity of symptoms and experiences related to each of these domains. The final item is an 11-point pain intensity numerical rating scale (NRS) by which the subject rates their average pain over the past 7 days. Subjects should read each item and check the one box that most closely represents their response.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by PROMIS-29</measure>
    <time_frame>5 Years</time_frame>
    <description>The PROMIS-29 is used to estimate overall quality of life by assessing the following domains known to impact activities of daily living: physical function, sleep disturbance, depression, anxiety, fatigue, pain interference, pain intensity, and social role satisfaction. The scale requires subjects to rate the frequency and/or severity of symptoms and experiences related to each of these domains. The final item is an 11-point pain intensity numerical rating scale (NRS) by which the subject rates their average pain over the past 7 days. Subjects should read each item and check the one box that most closely represents their response.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)</measure>
    <time_frame>6 months</time_frame>
    <description>The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)</measure>
    <time_frame>9 months</time_frame>
    <description>The pain NRS consists of 1 question that will be asked to the subjects via telephone calls. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)</measure>
    <time_frame>1 year</time_frame>
    <description>The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)</measure>
    <time_frame>1.5 years</time_frame>
    <description>The pain NRS consists of 1 question that will be asked to the subjects via telephone calls. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)</measure>
    <time_frame>2 Years</time_frame>
    <description>The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)</measure>
    <time_frame>2.5 Years</time_frame>
    <description>The pain NRS consists of 1 question that will be asked to the subjects via telephone calls. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)</measure>
    <time_frame>3 Years</time_frame>
    <description>The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)</measure>
    <time_frame>3.5 Years</time_frame>
    <description>The pain NRS consists of 1 question that will be asked to the subjects via telephone calls. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)</measure>
    <time_frame>4 Years</time_frame>
    <description>The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)</measure>
    <time_frame>4.5 Years</time_frame>
    <description>The pain NRS consists of 1 question that will be asked to the subjects via telephone calls. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)</measure>
    <time_frame>5 Years</time_frame>
    <description>The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>6 months</time_frame>
    <description>Pain Catastrophizing Scale is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'all the time'. The scale is self-administered and takes 5 minutes to complete. A higher score indicates a higher level of catastrophizing.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>1 Year</time_frame>
    <description>Pain Catastrophizing Scale is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'all the time'. The scale is self-administered and takes 5 minutes to complete. A higher score indicates a higher level of catastrophizing.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>2 Years</time_frame>
    <description>Pain Catastrophizing Scale is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'all the time'. The scale is self-administered and takes 5 minutes to complete. A higher score indicates a higher level of catastrophizing.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>3 Years</time_frame>
    <description>Pain Catastrophizing Scale is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'all the time'. The scale is self-administered and takes 5 minutes to complete. A higher score indicates a higher level of catastrophizing.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>4 Years</time_frame>
    <description>Pain Catastrophizing Scale is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'all the time'. The scale is self-administered and takes 5 minutes to complete. A higher score indicates a higher level of catastrophizing.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Catastrophizing Scale (PCS)</measure>
    <time_frame>5 Years</time_frame>
    <description>Pain Catastrophizing Scale is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'all the time'. The scale is self-administered and takes 5 minutes to complete. A higher score indicates a higher level of catastrophizing.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Oswestry Disability Index (ODI)</measure>
    <time_frame>6 months</time_frame>
    <description>The ODI is a 10-item scale that evaluates disability related to low-back and leg pain. It is widely used, validated, and has been translated into several languages. Each section in the scale covers a different domain (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling). Each item is scored on a scale from 0-5 with the first item scored a &quot;0&quot; and representing no disability. The final item is scored a &quot;5&quot; and represents the maximum level of disability. If more than one response in a section is checked, the highest score is chosen. The scores for each section are summed for a final score ranging from 0 to 50. If an item is not answered, the total score is instead calculated as a percentage of the total possible score for all items that were completed.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Oswestry Disability Index (ODI)</measure>
    <time_frame>1 Year</time_frame>
    <description>The ODI is a 10-item scale that evaluates disability related to low-back and leg pain. It is widely used, validated, and has been translated into several languages. Each section in the scale covers a different domain (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling). Each item is scored on a scale from 0-5 with the first item scored a &quot;0&quot; and representing no disability. The final item is scored a &quot;5&quot; and represents the maximum level of disability. If more than one response in a section is checked, the highest score is chosen. The scores for each section are summed for a final score ranging from 0 to 50. If an item is not answered, the total score is instead calculated as a percentage of the total possible score for all items that were completed.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Oswestry Disability Index (ODI)</measure>
    <time_frame>2 Years</time_frame>
    <description>The ODI is a 10-item scale that evaluates disability related to low-back and leg pain. It is widely used, validated, and has been translated into several languages. Each section in the scale covers a different domain (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling). Each item is scored on a scale from 0-5 with the first item scored a &quot;0&quot; and representing no disability. The final item is scored a &quot;5&quot; and represents the maximum level of disability. If more than one response in a section is checked, the highest score is chosen. The scores for each section are summed for a final score ranging from 0 to 50. If an item is not answered, the total score is instead calculated as a percentage of the total possible score for all items that were completed.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Oswestry Disability Index (ODI)</measure>
    <time_frame>3 Years</time_frame>
    <description>The ODI is a 10-item scale that evaluates disability related to low-back and leg pain. It is widely used, validated, and has been translated into several languages. Each section in the scale covers a different domain (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling). Each item is scored on a scale from 0-5 with the first item scored a &quot;0&quot; and representing no disability. The final item is scored a &quot;5&quot; and represents the maximum level of disability. If more than one response in a section is checked, the highest score is chosen. The scores for each section are summed for a final score ranging from 0 to 50. If an item is not answered, the total score is instead calculated as a percentage of the total possible score for all items that were completed.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Oswestry Disability Index (ODI)</measure>
    <time_frame>4 Years</time_frame>
    <description>The ODI is a 10-item scale that evaluates disability related to low-back and leg pain. It is widely used, validated, and has been translated into several languages. Each section in the scale covers a different domain (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling). Each item is scored on a scale from 0-5 with the first item scored a &quot;0&quot; and representing no disability. The final item is scored a &quot;5&quot; and represents the maximum level of disability. If more than one response in a section is checked, the highest score is chosen. The scores for each section are summed for a final score ranging from 0 to 50. If an item is not answered, the total score is instead calculated as a percentage of the total possible score for all items that were completed.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Oswestry Disability Index (ODI)</measure>
    <time_frame>5 Years</time_frame>
    <description>The ODI is a 10-item scale that evaluates disability related to low-back and leg pain. It is widely used, validated, and has been translated into several languages. Each section in the scale covers a different domain (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling). Each item is scored on a scale from 0-5 with the first item scored a &quot;0&quot; and representing no disability. The final item is scored a &quot;5&quot; and represents the maximum level of disability. If more than one response in a section is checked, the highest score is chosen. The scores for each section are summed for a final score ranging from 0 to 50. If an item is not answered, the total score is instead calculated as a percentage of the total possible score for all items that were completed.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by pain condition-related medication usage</measure>
    <time_frame>6 months</time_frame>
    <description>Pain condition-related medication usage (e.g. opioids, anti-convulsants, anti-depressants, sleep aids, topicals) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by pain condition-related medication usage</measure>
    <time_frame>1 Year</time_frame>
    <description>Pain condition-related medication usage (e.g. opioids, anti-convulsants, anti-depressants, sleep aids, topicals) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by pain condition-related medication usage</measure>
    <time_frame>2 Years</time_frame>
    <description>Pain condition-related medication usage (e.g. opioids, anti-convulsants, anti-depressants, sleep aids, topicals) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by pain condition-related medication usage</measure>
    <time_frame>3 Years</time_frame>
    <description>Pain condition-related medication usage (e.g. opioids, anti-convulsants, anti-depressants, sleep aids, topicals) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by pain condition-related medication usage</measure>
    <time_frame>4 Years</time_frame>
    <description>Pain condition-related medication usage (e.g. opioids, anti-convulsants, anti-depressants, sleep aids, topicals) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by pain condition-related medication usage</measure>
    <time_frame>5 Years</time_frame>
    <description>Pain condition-related medication usage (e.g. opioids, anti-convulsants, anti-depressants, sleep aids, topicals) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Transcutaneous Oxygen pressure measurement (TcPO2)</measure>
    <time_frame>6 months</time_frame>
    <description>Transcutaneous Oxygen pressure measurement (TcPO2) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Transcutaneous Oxygen pressure measurement (TcPO2)</measure>
    <time_frame>1 Year</time_frame>
    <description>Transcutaneous Oxygen pressure measurement (TcPO2) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Transcutaneous Oxygen pressure measurement (TcPO2)</measure>
    <time_frame>2 Years</time_frame>
    <description>Transcutaneous Oxygen pressure measurement (TcPO2) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Transcutaneous Oxygen pressure measurement (TcPO2)</measure>
    <time_frame>3 Years</time_frame>
    <description>Transcutaneous Oxygen pressure measurement (TcPO2) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Transcutaneous Oxygen pressure measurement (TcPO2)</measure>
    <time_frame>4 Years</time_frame>
    <description>Transcutaneous Oxygen pressure measurement (TcPO2) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Clinical improvement from baseline to each follow up visit assessed by Transcutaneous Oxygen pressure measurement (TcPO2)</measure>
    <time_frame>5 Years</time_frame>
    <description>Transcutaneous Oxygen pressure measurement (TcPO2) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of patient satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>Patient satisfaction will be summarized using counts and percentages&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of patient satisfaction</measure>
    <time_frame>1 Year</time_frame>
    <description>Patient satisfaction will be summarized using counts and percentages&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of patient satisfaction</measure>
    <time_frame>2 Years</time_frame>
    <description>Patient satisfaction will be summarized using counts and percentages&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of patient satisfaction</measure>
    <time_frame>3 Years</time_frame>
    <description>Patient satisfaction will be summarized using counts and percentages&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of patient satisfaction</measure>
    <time_frame>4 Years</time_frame>
    <description>Patient satisfaction will be summarized using counts and percentages&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of patient satisfaction</measure>
    <time_frame>5 Years</time_frame>
    <description>Patient satisfaction will be summarized using counts and percentages&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.</measure>
    <time_frame>6 months</time_frame>
    <description>The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via an interview technique. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.</measure>
    <time_frame>9 months</time_frame>
    <description>The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via telephone calls. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.</measure>
    <time_frame>1 Year</time_frame>
    <description>The PGIC is a categorical rating scale used to evaluate the subject'simpression of change in his/her condition since the beginning of thestudy treatment. The subject will be requested to rate their overallchange in activity limitations, symptoms, emotions and overall qualityof life related to his/her condition on a seven-point categorical scale via an interview technique. The categories are as follows: 1-nochange, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.</measure>
    <time_frame>1.5 Year</time_frame>
    <description>The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via telephone calls. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.</measure>
    <time_frame>2 Years</time_frame>
    <description>The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via an interview technique. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.</measure>
    <time_frame>2.5 Years</time_frame>
    <description>The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via telephone calls. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.</measure>
    <time_frame>3 Years</time_frame>
    <description>The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via an interview technique. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.</measure>
    <time_frame>3.5 Years</time_frame>
    <description>The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via telephone calls. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.</measure>
    <time_frame>4 Years</time_frame>
    <description>The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via an interview technique. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.</measure>
    <time_frame>4.5 Years</time_frame>
    <description>The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via telephone calls. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.</measure>
    <time_frame>5 Years</time_frame>
    <description>The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via an interview technique. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better.&#xD;
This study has no primary or secondary endpoints, all endpoints are of equal weight.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Spinal cord stimulation (SCS)</arm_group_label>
    <description>Subjects using Abbott SCS systems</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dorsal root ganglion stimulation (DRG)</arm_group_label>
    <description>Subjects using Abbott DRG system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spinal cord stimulation (SCS)</intervention_name>
    <description>Subjects will be implanted with market-released Abbott SCS systems</description>
    <arm_group_label>Spinal cord stimulation (SCS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dorsal root ganglion stimulation (DRG)</intervention_name>
    <description>Subjects will be implanted with market-released Abbott DRG system</description>
    <arm_group_label>Dorsal root ganglion stimulation (DRG)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This clinical investigation will enroll adult male and female individuals scheduled to have&#xD;
        an Abbott neurostimulation system implanted. Subjects must meet all eligibility criteria&#xD;
        and provide written informed consent prior to conducting any investigation-specific&#xD;
        procedures not considered standard of care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must provide written informed consent prior to any clinical investigation&#xD;
             related procedure.&#xD;
&#xD;
          2. Subject is at least 18 years (or the minimum age required by local law to consent for&#xD;
             participation in a clinical investigation) or older at the time of enrollment.&#xD;
&#xD;
          3. Subject is scheduled to have an Abbott neurostimulation system implanted within 60&#xD;
             days of baseline.&#xD;
&#xD;
          4. Subject has a baseline (with no stimulation) pain NRS of  6.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is enrolled, or intends to participate, in a competing clinical study, as&#xD;
             determined by Abbott.&#xD;
&#xD;
          2. Presence of other anatomic or comorbid conditions, or other medical, social, or&#xD;
             psychological conditions that, in the investigator's opinion, could limit the&#xD;
             subject's ability to participate in the clinical investigation or to comply with&#xD;
             follow-up requirements.&#xD;
&#xD;
          3. Subject has or is scheduled to receive an intrathecal pump.&#xD;
&#xD;
          4. Subject is part of a vulnerable population.&#xD;
&#xD;
          5. Subject has an existing implanted neuromodulation device to address their chronic&#xD;
             pain.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ann Jannu, PhD, CCRP</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Jannu, PhD, CCRP</last_name>
    <phone>+1 512 286 4199</phone>
    <email>Ann.Jannu@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Harbert</last_name>
    <phone>+1 972 526 4841</phone>
    <email>nicole.harbert@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenician Centers for Research &amp; Innovation</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tutankhamen Pappoe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pain Institute of Southern Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Cornidez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Orthopedics &amp; Spine</name>
      <address>
        <city>Larkspur</city>
        <state>California</state>
        <zip>94939</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ramana Naidu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Restore Orthopedics &amp; Spine Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Foothills Pain Management Clinic</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Pacific Research Institute</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason Pope</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Department of Anesthesia</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan Mora</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy Lubenow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Magdalena Anitescu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goodman Campbell Brain and Spine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Derron Wilson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nura</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Schultz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Twin Cities Pain Clinic</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Will</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Saint Louis Pain Consultants</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne Christopher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Pain Care</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Fishell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nevada Advanced Pain Specialists</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Denis Patterson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ainsworth Institute of Pain Management</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Corey Hunter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Spine Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hemant Kalia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Spine &amp; Pain Institute of New York</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kenneth Chapman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Pain Solutions</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javid Baksh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adena Bone and Joint Center</name>
      <address>
        <city>Chillicothe</city>
        <state>Ohio</state>
        <zip>45601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Premier Pain Treatment Institute</name>
      <address>
        <city>Loveland</city>
        <state>Ohio</state>
        <zip>45140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pacific Sports &amp; Spine</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gregory Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spinal Diagnostics</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Heros</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Interventional Pain &amp; Spine</name>
      <address>
        <city>Exton</city>
        <state>Pennsylvania</state>
        <zip>19341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Fishman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Expert Pain</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ioannis Skaribas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Texas Pain Institute</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <zip>76542</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pankaj Mehta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Pain Associates</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <zip>76542</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Pain Care</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78664</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Allen Dennis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Spine &amp; Nerve Center of St Francis Hospital</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy Deer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Pain Group</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dan Bates</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Precision Brain, Spine &amp; Pain Centre</name>
      <address>
        <city>Kew</city>
        <state>Victoria</state>
        <zip>3101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <state>Eflndrs</state>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Pierre Van Buyten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta vzw</name>
      <address>
        <city>Roeselare</city>
        <state>West Flanders</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bart Billet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitts Klinikum Tbingen</name>
      <address>
        <city>Tubingen</city>
        <state>Bad-wur</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthias Morgalla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Ingolstadt GmbH</name>
      <address>
        <city>Ingolstadt</city>
        <state>Bavaria</state>
        <zip>85049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Siamak Asgari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Duisburg GmbH</name>
      <address>
        <city>Duisburg</city>
        <state>N. Rhin</state>
        <zip>47055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Einrichtungen der Universitt Dsseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <state>N. Rhin</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Vesper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Neuwerk Maria von den Aposteln</name>
      <address>
        <city>Monchengladbach</city>
        <state>N. Rhin</state>
        <zip>41066</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bjoern Carsten Schultheis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Kln-Merheim</name>
      <address>
        <city>Koln</city>
        <state>North Rhine-Westphalia</state>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Faycal El Majdoub</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universittsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lbeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Gera -Zentrum fr interdisziplinre Schmerztherapie</name>
      <address>
        <city>Gera</city>
        <state>Thuringia</state>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Kretzschmar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Porz am Rhein</name>
      <address>
        <city>Koln</city>
        <zip>51149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas May</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Monaldi</name>
      <address>
        <city>Napoli</city>
        <state>Campani</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alfonso Papa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <state>Lombard</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laura Demartini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>S Holln</state>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>F.J.P.M Huygen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Harold Nijhuis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Cstleon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francisco Sanchez Montero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manuel Herrero</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agustin Mendiola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politcnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ma Angeles Cans Verdecho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich Hospital</name>
      <address>
        <city>Norwich</city>
        <state>England</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Walton Centre</name>
      <address>
        <city>Liverpool</city>
        <state>North West England</state>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Deepti Bhargava</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <state>Sowest</state>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seacroft Hospital</name>
      <address>
        <city>Leeds</city>
        <state>Yorkshire And The Humber</state>
        <zip>LS14 6UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ganesan Baranidharan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord stimulation</keyword>
  <keyword>dorsal root ganglion stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

